Vivo Capital

vivocapital.com

VCMatch tracks Vivo Capital as an investor focused on Biotech, Pharma, and Medtech companies, Seed and Series A rounds, and Global, Asia Pacific, and Greater China markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A, Series B, Growth, Late Stage

Focus Areas

Biotech, Pharma, Medtech

Geography

global, Asia Pacific, and Greater China

Investment Thesis

Vivo Capital positions itself as a specialist healthcare investor that pursues value across the full industry lifecycle by operating a multi-strategy platform (venture, private equity, public equity). The firm emphasizes creating proprietary opportunities and accelerating portfolio company growth through an “Ecosystem Strategy” and a resource-integration approach that leverages its network of portfolio companies, operating executives, industry partners and advisors to catalyze innovation, commercial scale-up, and expanded healthcare access globally.

Is Vivo Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Vivo Capital is most relevant for founders raising Seed, Series A, and Series B rounds in Biotech, Pharma, Medtech, and Digital Health, especially across global, Asia Pacific, and Greater China.

Focus statement

Vivo focuses on global healthcare investments across venture, growth/private equity and public equity — backing venture-stage, scale-up and small/mid-cap public life sciences companies and using tailored financing structures (PIPEs, follow-ons, registered directs, IPOs) to support commercialization and growth.

Value Add

Multi-strategy platform covering venture capital, private equity and public equity strategies (explicitly stated: "multi-strategy investment platform covering venture capital, private equity and public equity strategies").
Ecosystem / resource-integration approach: "tapping into the ecosystem of portfolio companies and resources within our network" to facilitate international partnerships and cross-value chain collaborations.
Global footprint and cross-border capability: "We invest globally" and emphasize international partnerships and cross-value chain collaborations.
Operating and commercial scale-up focus in private equity: emphasis on underwriting operational and commercial scale-up and buyouts where control can be acquired.
Dedicated funds with clear mandates: e.g., Vivo Innovation Fund for venture-stage, Vivo Opportunity Fund for long-only small/mid-cap public equities, and distinct growth, buyout and PE strategies.
Demonstrated track record and scale: 29+ years in business, 430+ global investments, 100+ IPOs and M&As, 65+ regulatory approvals, and $5.3bn active AUM (as of Q4 2024).
Flexible financing toolkit for public investments: often invests via "follow-ons, PIPEs, registered directs, and IPOs."